Table 1.
Baseline characteristics in KorAHF registry and VICTORIA patients
| Characteristics | KorAHF | VICTORIA |
|---|---|---|
| (N = 3014) | (N = 5050) | |
| Male (%) | 58.4% | 76.4% |
| Age (years) | 67 ± 15 | 67 ± 12 |
| BMI (kg/m2) | 23.2 ± 3.8 | 27.8 ± 5.9 |
| Ischaemic origin (%) | 41.8% | 58.3% |
| Diabetes (%) | 36.2% | 46.9% |
| Hypertension (%) | 56.2% | 79.1% |
| COPD (%) | 10.4% | 17.2% |
| Atrial fibrillation (%) | 29.8% | 44.9% |
| Systolic blood pressure (mmHg) | 114 ± 19 | 121 ± 16 |
| Diastolic blood pressure (mmHg) | 67 ± 13 | 73 ± 11 |
| Heart rate (b.p.m.) | 81 ± 17 | 73 ± 13 |
| LVEF (%) | 28.7 ± 8.7 | 28.9 ± 8.3 |
| eGFR (mL/min/1.73 m2) | 68.2 ± 34.0 | 61.5 ± 27.2 |
| >60 (%) | 58.7% | 47.1% |
| >30 to ≤60 (%) | 29.5% | 42.7% |
| ≤30 (%) | 11.8% | 10.2% |
| Haemoglobin (g/dL) | 12.7 ± 2.2 | 13.4 ± 1.9 |
| Sodium (mmol/L) | 138.4 ± 3.8 | 139.9 ± 3.4 |
| Potassium (mmol/L) | 4.5 ± 0.6 | 4.5 ± 0.5 |
| BNP (pg/mL) | 1040 [544–1730] | |
| NT‐proBNP (pg/mL) | 3544 [1875–8052] | 2816 [1556–5314] |
| Heart failure treatments | ||
| ACEi/ARB/ARNI (%) | 77.2% | 87.9% |
| BB (%) | 58.3% | 93.1% |
| MRA (%) | 51.2% | 70.3% |
ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BB, beta‐blocker; BMI, body mass index; BNP, B‐type natriuretic peptide; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; KorAHF, Korean Acute Heart Failure registry; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; VICTORIA, Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction.